Insider Selling: Cellebrite DI (NASDAQ:CLBT) CMO Sells 2,198 Shares

Key Points

• Cellebrite DI’s CMO David Nicholas Gee sold 2,198 shares at an average price of $11.24, totaling $24,705.52. He retained 139,604 shares after the transaction, a 1.55% reduction in his direct ownership.
• CLBT shares rose 4.0% to $11.49, although the stock remains below its 50-day and 200-day moving averages and has traded between $9.58 and $19.98 over the past year.
• Analysts remain broadly positive, with five Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $16.70. Several firms recently reduced their targets following the company’s results.

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CMO David Nicholas Gee sold 2,198 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $11.24, for a total transaction of $24,705.52. Following the completion of the transaction, the chief marketing officer directly owned 139,604 shares of the company's stock, valued at approximately $1,569,148.96. This trade represents a 1.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

David Nicholas Gee also recently made the following trade(s):

• On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The stock was sold at an average price of $16.07, for a total value of $3,696.10.

Cellebrite DI Stock Up 4.0%

Shares of CLBT traded up $0.44 on Monday, reaching $11.49. The stock had a trading volume of 3,463,245 shares, compared to its average volume of 2,270,829. Cellebrite DI Ltd. has a twelve month low of $9.58 and a twelve month high of $19.98. The firm has a market capitalization of $2.87 billion, a PE ratio of 52.23, a PEG ratio of 1.53 and a beta of 1.18. The firm has a 50-day moving average of $14.27 and a 200 day moving average of $13.85.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on CLBT shares. JPMorgan Chase & Co. decreased their price objective on shares of Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating on the stock in a research report on Friday, August 14th. DA Davidson lowered their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. Weiss Ratings downgraded Cellebrite DI from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, August 13th. Needham & Company LLC lowered their target price on Cellebrite DI from $15.00 to $12.50 and set a "buy" rating on the stock in a report on Friday, August 14th. Finally, Lake Street Capital dropped their price target on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.70.

Hedge Funds Weigh In On Cellebrite DI

Several institutional investors and hedge funds have recently modified their holdings of the company. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its stake in Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company's stock worth $34,000 after acquiring an additional 850 shares during the period. Advisory Services Network LLC purchased a new stake in shares of Cellebrite DI in the third quarter valued at $40,000. CWM LLC lifted its position in Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company's stock worth $44,000 after buying an additional 889 shares during the period. Elevation Wealth Partners LLC acquired a new stake in Cellebrite DI in the 2nd quarter worth about $44,000. Finally, Vestcor Inc acquired a new stake in Cellebrite DI in the 3rd quarter worth about $70,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source